Esperion Therapeutics (ESPR) Receivables - Net: 2020-2025
Historic Receivables - Net for Esperion Therapeutics (ESPR) over the last 5 years, with Sep 2025 value amounting to $119.0 million.
- Esperion Therapeutics' Receivables - Net rose 75.42% to $119.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.0 million, marking a year-over-year increase of 75.42%. This contributed to the annual value of $80.1 million for FY2024, which is 65.26% up from last year.
- Esperion Therapeutics' Receivables - Net amounted to $119.0 million in Q3 2025, which was up 10.43% from $107.7 million recorded in Q2 2025.
- In the past 5 years, Esperion Therapeutics' Receivables - Net registered a high of $119.0 million during Q3 2025, and its lowest value of $17.3 million during Q1 2021.
- For the 3-year period, Esperion Therapeutics' Receivables - Net averaged around $67.2 million, with its median value being $60.4 million (2024).
- Data for Esperion Therapeutics' Receivables - Net shows a peak YoY spiked of 85.13% (in 2021) over the last 5 years.
- Quarterly analysis of 5 years shows Esperion Therapeutics' Receivables - Net stood at $22.9 million in 2021, then surged by 47.07% to $33.7 million in 2022, then surged by 43.78% to $48.5 million in 2023, then skyrocketed by 65.26% to $80.1 million in 2024, then spiked by 75.42% to $119.0 million in 2025.
- Its Receivables - Net was $119.0 million in Q3 2025, compared to $107.7 million in Q2 2025 and $81.3 million in Q1 2025.